fig3

Figure 3. Differential FGFR2 expression partially determines cryptotanshinone sensitivity in ATP6V0D1-deficient cells. (A and B) Western blot analysis of indicated proteins after treatment (Drug concentrations: JTC801, 3.5 μM; Crypto, 5 μM; LY2874455, 450 nM; treatment time: 24 h); (C) CCK-8 assay of cell viability after JTC801, LY2874455, or combination treatment (same concentrations and time as above); (D) Cell death assay showing mortality after JTC801, LY2874455, or combination treatment; (E) CCK-8 assay evaluating cell viability of SW1990 cells treated with Crypto (5 μM) after ATP6V0D1 knockout or combined ATP6V0D1 and FGFR2 knockout; (F) Cell death assay for the indicated groups (Drug concentration: Crypto, 5 μM; treatment time: 24 h). Data (C-E) are shown as mean ± SD from three or more biologically independent samples (C and D, n = 3; E, n = 6; F, n = 3). Statistical significance was performed using two-way ANOVA with Tukey’s multiple comparisons test. Western blots (A and B) represent three independent experiments. Source data are provided. ^*P < 0.05 was considered statistically significant; ns: not significant. FGFR2: Fibroblast growth factor receptor 2; ATP6V0D1: ATPase H⁺ transporting V0 subunit D1; SD: standard deviation; ANOVA: analysis of variance.